PCCTC Investigators Showcase Groundbreaking Research at 2026 ASCO GU Symposium
Multiple Abstracts Highlight The PCCTC's Leadership in Advancing Prostate Cancer Clinical Trials and Treatment Standards
The Prostate Cancer Clinical Trials Consortium (PCCTC) today announced that its investigators will present multiple significant research findings at the 2026 American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), February 26-28, 2026. This recognition underscores the PCCTC's mission to design, implement, and complete innovative process-driven clinical studies that translate scientific discoveries into improved standards of care for prostate cancer patients.
The PCCTC's work will be featured across multiple presentation formats, demonstrating the breadth and impact of the consortium's research efforts:
Oral Abstract Session A: Prostate Cancer (8:05 – 9:45 AM)
Abstract #16: "Overall Survival from the Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC) with DNA Repair Defects (BRCAAway)"
Presenter: Maha H. A. Hussain, MD, FASCO, FACP
Poster Session A: Prostate Cancer (11:30 AM – 12:45 PM)
Abstract #86 (Poster Board B19): "Real-world use of novel hormonal therapies in European and North American patients with metastatic hormone-sensitive prostate cancer (mHSPC) [IRONMAN]"
Presenter: Zdravko Vassilev, MD, MPH
Abstract #100 (Poster Board C7): "Sequencing of therapeutic agents before and after metastatic castration-resistant prostate cancer (mCRPC) diagnosis in an international real-world setting [IRONMAN]"
Presenter: Rana R. McKay, MD, FASCO
Abstract #139 (Poster Board D20): "Prognostic significance of depressive symptoms in men with advanced prostate cancer: Results from the IRONMAN registry"
Presenter: Elizabeth Tran, BS
Abstract #162 (Poster Board E17): "Trial design and objectives for prostate cancer: Recommendations from the Prostate Cancer Clinical Trials Working Group 4 (PCWG4)"
Presenter: Andrew Armstrong, MD, MSc
Abstract #183 (Poster Board F12): "A multicohort phase 2 trial of androgen deprivation therapy (ADT), docetaxel, and nivolumab in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumors and DNA damage repair (DDR) alterations"
Presenting Author: Xiao X. Wei, MD
"The collaborative nature and intellectual synergy of our investigators position the PCCTC to make a significant impact on the lives of patients by keeping the pipeline primed with the most promising novel therapies and validated biomarkers," said Jake Vinson, PCCTC CEO. "The breadth of research being presented at ASCO GU — from landmark clinical trials to real-world evidence studies and updated trial design standards — demonstrates our commitment to advancing every aspect of prostate cancer care and clinical research."
The presentations span critical areas including combination therapies for DNA repair defects, real-world treatment patterns, quality of life assessments, innovative trial designs combining immunotherapy with standard treatments, and updated global standards for clinical trial conduct through the PCWG4 recommendations.
For more information about the PCCTC presentations at the 2026 ASCO GU Symposium, visit https://www.asco.org/gu. To learn more about the PCCTC, visit https://www.pcctc.org/.
